ALK and lung carcinoma: Three hundred and forty-seven patients with locally advanced or metastatic ALK-positive lung cancers who had received one prior treatment, were given 250 mg oral crizotinib BID or intravenous chemotherapy with either pemetrexed or docetaxel every three weeks.